ReviewFrontiers in immunology2024
Inflammation mechanism and research progress of COPD.
Review in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 166 papers, 10 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
166 citing papers in PubMed, 10 syntheses or guidelines pooled it.
- Association between serum uric acid levels and COPD: a meta-analysis and mendelian randomization study.BMC pulmonary medicine · 2026Pooled it
- Incidence and Risk Factors for Progression from Pre-COPD to COPD: A Systematic Review and Meta‑analysis.International journal of chronic obstructive pulmonary disease · 2026Pooled it
- Pooled it
- Cell-type specificity of Tim-3 in respiratory diseases: from mechanisms to clinical translation.Frontiers in immunology · 2026Pooled it
- Anti-type 2 monoclonal antibody therapy for eosinophilic COPD beyond triple therapy: a systematic review and meta-analysis with strict eosinophil inclusion criteria.Frontiers in medicine · 2026Pooled it
- Associations of the systemic immune-inflammation index and systemic inflammatory response index with chronic obstructive pulmonary disease: a systematic review and meta-analysis.Frontiers in medicine · 2026Pooled it
- Exercise Training Improves Depression and Anxiety in Patients with COPD: A Dose-Response Meta-Analysis of Randomized Controlled Trials.International journal of chronic obstructive pulmonary disease · 2026Pooled it
- The role of COPD in survival of NSCLC patients receiving immune checkpoint inhibitors: A meta-analysis.Biomolecules & biomedicine · 2025Pooled it
- Predictive value of neutrophil-lymphocyte ratio for all-cause mortality in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.BMC pulmonary medicine · 2025Pooled it
- Changes in Retinal Nerve Fiber Layer Thickness in Patients With Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis.The clinical respiratory journal · 2025Pooled it
- Pharmacokinetics, Safety and Tolerability of HPP737, a Novel PDE4 Inhibitor, in Healthy Chinese Participants: Phase I Study.Drug design, development and therapy · 2026Trial
- Review
- Advances in sirtuin research in lung diseases (Review).International journal of molecular medicine · 2026Review
- Myrtenol inhalation ameliorates lung injury induced by cigarette smoke in rats: the role of inflammation and oxidative stress.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Geometric and quantum kernel methods for predicting skeletal muscle outcomes in experimental chronic obstructive pulmonary disease.Scientific reports · 2026Article
- Oxidative Stress and Inflammatory Cytokines as Drivers of Cardiac Remodeling in COPD Patients.Antioxidants (Basel, Switzerland) · 2026Article
- Precision nanomedicine for pulmonary diseases: from molecular targeting to clinical translation.Signal transduction and targeted therapy · 2026Review
- Machine learning-based MPO and Lp-PLA2 profiling reveals asthma-predominant inflammatory signature in asthma-COPD overlap.The World Allergy Organization journal · 2026Article
- From Airway Inflammation to Molecular Remodeling: Integrating YKL-40, MBL and Epigenetic Biomarkers in Asthma and COPD.Biomolecules · 2026Review
- Quercetin in COPD: A Multi-Target Approach to Modulate Inflammation, Oxidative Stress, and Epithelial Dysfunction.International journal of molecular sciences · 2026Review
106 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic obstructive pulmonary disease (COPD) is a common respiratory disease characterized by irreversible progressive airflow limitation, often manifested by persistent cough, sputum production and other respiratory symptoms that pose a serious threat to human health and affect the quality of life of patients. The disease is associated with chronic inflammation, which is associated with the onset and progression of COPD, but anti-inflammatory therapy is not first-line treatment. Inflammation has multiple manifestations and phenotypes, and this heterogeneity reveals different patterns of inflammation, making treatment difficult. This paper aims to explore the direction of more effective anti-inflammatory treatment by analyzing the nature of inflammation and the molecular mechanism of disease occurrence and development in COPD patients, and to provide new ideas for the treatment of COPD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.